BRCA2 Knockout BT-549 Cell Line

The choice depends on whether you are studying BRCA2's role as the principal RAD51-loading factor for homologous recombination or modeling BRCA2-deficient cancers for PARP inhibitor synthetic lethality. The Knockout line is the standard tool for asking whether BRCA2 is required for these processes — BRCA2 is a critical homologous recombination (HR) repair factor that, together with PALB2 and DSS1, loads RAD51 onto resected single-stranded DNA at double-strand break sites; BRCA2 contains the BRC repeats (RAD51 binding) and DNA-binding domain. BRCA2 germline mutations cause hereditary breast and ovarian cancer syndrome (HBOC) with substantially elevated lifetime cancer risk; BRCA2 is also implicated in Fanconi anemia complementation group D1 (biallelic mutations) and prostate, pancreatic cancer predisposition. Overexpression is useful for studying BRCA2 in heterologous expression contexts. For HR-deficient cancer therapy research, the EDITGENE BRCA2 Knockout in BT-549 is uniquely valuable — BT-549 is a triple-negative breast cancer (TNBC) cell line, providing a clinically relevant context for HR-deficient cancer research. Rescue with wild-type or patient-derived BRCA2 mutations enables disease modeling. The knockout is a critical specificity control for ⭐⭐⭐ PARP inhibitors: ⭐⭐⭐ olaparib (Lynparza), talazoparib (Talzenna), niraparib (Zejula), rucaparib (Rubraca) — the foundational PARP inhibitor class for BRCA-mutated breast, ovarian, prostate, and pancreatic cancers exploiting synthetic lethality.

Primary applications: • PARP inhibitor synthetic lethality: critical genetic background for ⭐⭐⭐ olaparib (Lynparza), talazoparib (Talzenna), niraparib (Zejula), rucaparib (Rubraca) sensitivity testing — BRCA2-null TNBC should show profound PARP inhibitor hypersensitivity. • HR deficiency studies: RAD51 foci formation and IR-induced DSB repair analysis. • PARP inhibitor resistance: rescue with BRCA2 reversion mutations (clinically observed PARP inhibitor resistance mechanism) enables resistance modeling. • TNBC modeling: in BT-549 TNBC context, BRCA2-null phenotypes relevant for hereditary breast cancer biology. EDITGENE recommends this BT-549 TNBC-based model as the gold-standard genetic null for PARP inhibitor research and HR-deficient cancer therapy development.

Yes, with significant technical considerations for this very large protein: • Construct design: BRCA2 is a ~3,418 aa protein (~390 kDa) with 8 BRC repeats (RAD51 binding), DNA-binding domain (DBD), and OB-folds — full-length cDNA rescue is technically challenging due to the >10 kb mRNA size. • Domain-focused rescue: BRC repeat regions or partial BRCA2 constructs may be more tractable for specific functional rescue. • PARP inhibitor sensitivity rescue: WT BRCA2 rescue should restore HR proficiency and PARP inhibitor resistance — provides on-target PARP inhibitor validation. • BRCA2 reversion mutation rescue: clinically observed reversion mutations enable PARP inhibitor resistance mechanism studies. • Functional readout: rescue should restore RAD51 foci formation and IR-induced HR repair. BT-549-specific considerations: • BT-549 is a human triple-negative breast cancer (TNBC) cell line with characteristic basal-like features — relevant for TNBC biology, BRCA-deficient cancer modeling, and PARP inhibitor research. • Lentiviral transduction is supported with moderate efficiency. • BT-549 has TP53 mutation and other features of aggressive TNBC.